Ligand Pharmaceuticals LGND Interest Expense
Interest Expense at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's interest expense?
- Ligand Pharmaceuticals (LGND) reported interest expense of $1.75M in Q1 2026.
- How has Ligand Pharmaceuticals's interest expense changed year-over-year?
- Ligand Pharmaceuticals's interest expense increased by 101.5% year-over-year, from $867K to $1.75M.
- What is the long-term trend for Ligand Pharmaceuticals's interest expense?
- Over 4 years (2021 to 2025), Ligand Pharmaceuticals's interest expense has grown at a -30.0% compound annual growth rate (CAGR), from $19.62M to $4.72M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.